Loading clinical trials...
Loading clinical trials...
Bleb Vascularity Change After Subconjunctival Injection of Bevacizumab
The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.
Age
18 - 80 years
Sex
ALL
Healthy Volunteers
No
Tongren hospital
Beijing, Beijing Municipality, China
Start Date
December 1, 2008
Primary Completion Date
March 1, 2009
Completion Date
May 1, 2009
Last Updated
December 30, 2008
30
ESTIMATED participants
bevacizumab
DRUG
Lead Sponsor
Capital Medical University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions